Research programme: meningococcus vaccine - Novartis

Drug Profile

Research programme: meningococcus vaccine - Novartis

Latest Information Update: 11 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Research Council Canada; University of Oxford
  • Developer Novartis Vaccines
  • Class Vaccines
  • Mechanism of Action Lipopolysaccharide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Meningococcal infections

Most Recent Events

  • 11 Aug 2011 No development reported - Preclinical for Meningococcal infections in USA (Parenteral)
  • 18 Dec 2008 Preclinical trials in Meningococcal infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top